Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 03:40PM GMT
Release Date Price: €146.42 (+0.03%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

This morning, welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the Smid biotech analysts here at the firm.

It's my pleasure to introduce Sage Therapeutics. Sitting next to me is Jeff Jonas, CEO of the company. And sitting next to him is Mike Cloonan, who is Chief Business Officer. This is going to be a Q&A session. So feel free to raise your hand and ask any questions from the audience. But I will start off the conversation. And maybe just for those very few people who are not as familiar with Sage as the rest of us might be, maybe you could give us a 2-minute introduction about the company, and then we can go from there.

Jeffrey M. Jonas
Sage Therapeutics, Inc. - CEO, President & Director

Will do. Thanks. Everyone can hear me, I'm assuming. So thanks, everybody, for coming. The -- so those of you who don't know Sage, we're a company that's focused on central nervous system diseases. We've been public for about 4 years. We recently just announced we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot